Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial
Official title:
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study
CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive subgroup of patients with serum autoantibodies to the paranodal proteins contactin and neurofascin have been identified. Although they present with active and serious disease, multiple clinical reports suggest that these patients can be cured with a treatment that depletes B cells and presumably eliminates pathogenic autoantibodies. However, beyond that subgroup of CIDP patients, which CIDP patients might benefit from Rituximab and B cell depletion is unknown. This Phase II study will treat 3 homogenous groups of 16 CIDP patients each with Rituximab in order to determine if there are subgroups that can be taken off current medications and put into long-term remission. The results from this study will be used to design a future larger trial. Biomarkers including paranodal antibodies, serum neurofilament light chains, anti-ganglioside antibodies will be obtained in order to learn about disease pathogenesis and possibly target therapy
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02465359 -
Subcutaneous Immunoglobulin for CIDP
|
N/A | |
| Recruiting |
NCT05584631 -
IVIG vs SCIG in CIDP
|
Phase 1 | |
| Withdrawn |
NCT01236456 -
High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Terminated |
NCT03779828 -
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
|
||
| Completed |
NCT01184846 -
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | |
| Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
| Recruiting |
NCT06290141 -
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
| Completed |
NCT01379833 -
Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
|
||
| Completed |
NCT02414490 -
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
|
||
| Completed |
NCT01545076 -
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
|
Phase 3 | |
| Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
| Recruiting |
NCT04672733 -
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
|
||
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Not yet recruiting |
NCT05219383 -
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
|
||
| Completed |
NCT02111590 -
Immunoglobulin Dosage and Administration Form in CIDP and MMN
|
N/A | |
| Recruiting |
NCT04292834 -
A Registered Cohort Study of Immune-Mediated Neuropathies
|
||
| Terminated |
NCT03772717 -
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
N/A | |
| Completed |
NCT00278629 -
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Recruiting |
NCT02372149 -
IVIg for Demyelination in Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT00962429 -
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 |